CN105878331A - Polysaccharide composition and preparation method and application thereof - Google Patents
Polysaccharide composition and preparation method and application thereof Download PDFInfo
- Publication number
- CN105878331A CN105878331A CN201610379155.XA CN201610379155A CN105878331A CN 105878331 A CN105878331 A CN 105878331A CN 201610379155 A CN201610379155 A CN 201610379155A CN 105878331 A CN105878331 A CN 105878331A
- Authority
- CN
- China
- Prior art keywords
- flos lonicerae
- chinese medicine
- medicine composition
- lentinan
- polysaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000004676 glycans Chemical class 0.000 title claims abstract description 96
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 78
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 78
- 239000000203 mixture Substances 0.000 title claims abstract description 71
- 238000002360 preparation method Methods 0.000 title claims abstract description 58
- 241000628997 Flos Species 0.000 claims abstract description 91
- 229920001491 Lentinan Polymers 0.000 claims abstract description 77
- 229940115286 lentinan Drugs 0.000 claims abstract description 77
- 239000003814 drug Substances 0.000 claims abstract description 62
- 208000021735 chronic enteritis Diseases 0.000 claims abstract description 27
- 240000000599 Lentinula edodes Species 0.000 claims abstract description 22
- 206010000059 abdominal discomfort Diseases 0.000 claims abstract description 12
- 235000001715 Lentinula edodes Nutrition 0.000 claims description 21
- 235000013402 health food Nutrition 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 13
- 230000002265 prevention Effects 0.000 claims description 13
- 238000005352 clarification Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 2
- 239000013049 sediment Substances 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 23
- 238000000034 method Methods 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 15
- 238000002474 experimental method Methods 0.000 abstract description 11
- 230000000968 intestinal effect Effects 0.000 abstract description 4
- 210000001156 gastric mucosa Anatomy 0.000 abstract description 3
- 235000016709 nutrition Nutrition 0.000 abstract description 2
- 230000000295 complement effect Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 43
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 25
- 241000700159 Rattus Species 0.000 description 20
- 150000004804 polysaccharides Polymers 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 238000010171 animal model Methods 0.000 description 12
- 210000001072 colon Anatomy 0.000 description 12
- 230000003449 preventive effect Effects 0.000 description 9
- 229960004756 ethanol Drugs 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 230000001684 chronic effect Effects 0.000 description 7
- 206010009887 colitis Diseases 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 241000190633 Cordyceps Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000009266 disease activity Effects 0.000 description 5
- 239000003651 drinking water Substances 0.000 description 5
- 235000020188 drinking water Nutrition 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000000112 colonic effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- 239000010931 gold Substances 0.000 description 4
- PQTCMBYFWMFIGM-UHFFFAOYSA-N gold silver Chemical compound [Ag].[Au] PQTCMBYFWMFIGM-UHFFFAOYSA-N 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 231100000957 no side effect Toxicity 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 229960002275 pentobarbital sodium Drugs 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 235000008935 nutritious Nutrition 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 3
- 229960001940 sulfasalazine Drugs 0.000 description 3
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 208000031295 Animal disease Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 230000001200 fecal consistency Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000007365 immunoregulation Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010057669 Colon injury Diseases 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000031856 Haemosiderosis Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241001492261 Pleurotaceae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 150000001323 aldoses Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 210000004921 distal colon Anatomy 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000002338 glycosides Chemical group 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 150000002584 ketoses Chemical class 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the field of healthcare food, in particular to a traditional Chinese medicine composition and a preparation method and application thereof and medicine and healthcare food containing the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from shiitake mushrooms and flos lonicerae or prepared from lentinan and flos lonicerae polysaccharides. Experiments show that the traditional Chinese medicine composition or the medicine or the healthcare food prepared through the method is prepared through scientific compatibility, complement each other, is free of toxic and side effects, not only has the nutritional value, but also has the function of preventing and improving chronic enteritis and gastrointestinal discomfort caused by the chronic enteritis, also can regulate intestinal floras and has the auxiliary protection effect on the gastric mucosa.
Description
Technical field
The present invention relates to field of health care food, particularly to Chinese medicine composition and preparation method thereof, purposes with
And containing the medicine of this Chinese medicine composition, health food.
Background technology
Ulcerative colitis is a kind of common chronic intestinal disease, is also a kind of multifactor, multi-level
Agnogenic nonspecific inflammation, its etiology unknown, course of disease delay difficulty heals, recurrent exerbation.Mainly face
Bed shows as stomachache, diarrhoea, mucus bloody purulent stool etc., and domestic and international epidemic data shows, exedens knot
Enteritis sickness rate and prevalence all present and significantly increase trend, are classified as modern refractory by World Health Organization (WHO)
One of sick.Ulcerative colitis is many to be pressed down with minosalicylates, drugs, Adrenal Glucocorticoid, immunity
Preparations etc. are main, but curative effect of medication is the best mostly, and have certain side effect.And polysaccharide is as natural height
Molecular compound, is formed by connecting by glycosides chain by aldose or ketose, be Chinese herbal medicine main active it
One, wide material sources and also nontoxic, have immunomodulating, antiinflammatory, antitumor, defying age, antioxidation,
The pharmacologically actives such as blood fat reducing and pharmacodynamic feature.Herbal polysaccharide is in the Related Research Domain of ulcerative colitis
It is increasingly subject to pay attention to.
Lentinus Edodes has another name called Lentinus Edodes, Lentinus Edodes, fragrant bacterium etc., for the sporophore of Pleurotaceae plant Lentinus Edodes, is the world the
Two big edible fungi, have the title of " king of delicacy from mountain ", are high protein, low-fat nutritional health food.China is gone through
For physician, Lentinus Edodes all had famous discussion.Modern medicine and threpsology deepen continuously research, the medicine of Lentinus Edodes
The most constantly it is exploited with being worth.In Lentinus Edodes, Quantitative Determination of Ergosterol is the highest, effective to preventing and treating rickets；Lentinus Edodes
Polysaccharide can strengthen cell immunocompetent.
Flos Lonicerae, has another name called Radix Ophiopogonis.Flos Lonicerae has effect of heat-clearing and toxic substances removing, wind-heat dissipating, cures mainly carbuncle
Furuncle, sore throat, erysipelas, toxic-heat and blood stasis, anemopyretic cold, epidemic febrile disease heating etc..There is abundant pharmacology live
Property, and have no side effect, it is widely used to clinic.Flos Lonicerae aboundresources, it is the biggest to be that one has
The Chinese medicine of potentiality to be exploited, through modern age pharmacological evaluation and clinical practice prove, Flos Lonicerae has for multiple pathogenic bacteria
Stronger antibacterial action and preferable therapeutic effect.Polysaccharide is one of Flos Lonicerae composition, and Flos Lonicerae polysaccharide has
There is obvious immunological enhancement, and drug effect exists dependency with dosage.
Summary of the invention
In view of this, the present invention provides Chinese medicine composition and preparation method thereof, purposes and contains this Chinese medicine
The medicine of compositions, health food.The Chinese medicine composition of gained of the present invention, medicine or health food are through section
Compatibility forms, and brings out the best in each other, and has no side effect.The most nutritious, there is again prevention and improve chronic
Enteritis and the gastrointestinal upset function caused thereof, moreover it is possible to regulating intestinal canal flora, have auxiliary protection to make gastric mucosa
With.
In order to realize foregoing invention purpose, the present invention provides techniques below scheme:
The invention provides a kind of Chinese medicine composition, be made up of Lentinus Edodes and Flos Lonicerae.
In some specific embodiments of the present invention, the effective ingredient of Lentinus Edodes described in Chinese medicine composition is
Lentinan, the effective ingredient of described Flos Lonicerae is Flos Lonicerae polysaccharide.
In some specific embodiments of the present invention, lentinan described in Chinese medicine composition and described gold
The mass ratio of Flos Lonicerae polysaccharide is (1:5)～(5:1).
In some specific embodiments of the present invention, lentinan described in Chinese medicine composition and described gold
The mass ratio of Flos Lonicerae polysaccharide is (2:4)～(4:2).
In some specific embodiments of the present invention, lentinan described in Chinese medicine composition and described gold
The mass ratio of Flos Lonicerae polysaccharide is 2:3.
In some specific embodiments of the present invention, lentinan described in Chinese medicine composition and described gold
Flos Lonicerae polysaccharide is natural or synthetic.
Present invention also offers the preparation method of described Chinese medicine composition, take described Lentinus Edodes or described gold silver
Pollen is broken, in terms of g/mL, is (0.5g～2.0g) according to the mass volume ratio of Lentinus Edodes or Flos Lonicerae and water:
The ratio mixing of 5mL, extracts 3h at 70 DEG C～75 DEG C of heated and stirred, filters the filtering residue obtained according to above-mentioned
Solid-liquid ratio, temperature and time continue extraction twice, merge three extracting solution, through concentrating under reduced pressure with centrifugal
Obtain clarification concentrated solution, be 1 according to the volume ratio of described clarification concentrated solution and 95% ethanol: (7～10) mix
Close, precipitate in 4 DEG C of overnight stand after mixing, centrifugal collecting precipitation, through vacuum lyophilization and get final product.
Present invention also offers the Chinese medicine composition that described preparation method prepares.
Present invention also offers the Chinese medicine composition that described Chinese medicine composition and/or described preparation method prepare
In preparation prevention and/or improve in chronic enteritis and the medicine of gastrointestinal upset caused thereof and/or health food
Purposes.
So-called gastrointestinal upset, including upper abdomen gastral cavilty portion discomfort, stomach pain, the most glutted, belch, returns
Acid, Nausea and vomiting, dyspepsia, the intestines and stomach angor.
In some specific embodiments of the present invention, lentinan described in described Chinese medicine composition and institute
The using dosage stating Flos Lonicerae polysaccharide is respectively 300mg/kg.
Present invention also offers a kind of for preventing and/or improve chronic enteritis and the gastrointestinal upset that causes thereof
Medicine and/or health food, including described Chinese medicine composition and/or described preparation method prepare described
Chinese medicine composition and pharmaceutically acceptable adjuvant.
Described pharmaceutically acceptable adjuvant includes carrier, excipient, excipient and/or filler.
In some specific embodiments of the present invention, the dosage form of described medicine or described health food is glue
Capsule, tablet, granule, oral liquid, powder, teabag.
The invention provides a kind of Chinese medicine composition, be made up of the Radix Astragali and Radix Ophiopogonis.Experiment shows, the present invention
The Chinese medicine composition, medicine or the health food that prepare form through scientific compatibility, bring out the best in each other, nontoxic secondary work
With.The most nutritious, there is again prevention and improve chronic enteritis and the gastrointestinal upset function caused thereof, also
Energy regulating intestinal canal flora, has auxiliary protection function to gastric mucosa.
Detailed description of the invention
The invention discloses Chinese medicine composition and preparation method thereof, purposes and contain this Chinese medicine composition
Medicine, health food, those skilled in the art can use for reference present disclosure, is suitably modified technological parameter real
Existing.Special needs to be pointed out is, all similar replacements and change are aobvious for a person skilled in the art
And be clear to, they are considered as being included in the present invention.Method and the application of the present invention have been passed through preferably
Embodiment is described, and related personnel substantially can be right in without departing from present invention, spirit and scope
Method described herein and application are modified or suitably change and combine, and realize and apply skill of the present invention
Art.
According to a first aspect of the present invention, it is provided that a kind of health-care food composition, described compositions comprises perfume (or spice)
Mushroom polysaccharide and Flos Lonicerae polysaccharide, the ratio mixing of 2:3, optionally farther includes pharmacy the most by weight
Or food acceptable carrier, excipient, adjuvant and/or filler.
Present aspect one preferred embodiment in, described lentinan or Flos Lonicerae polysaccharide are natural
Or synthetic.
According to a second aspect of the present invention, it is provided that the preparation method of a kind of health-care food composition, described method
Including, most preferably mix lentinan and the Flos Lonicerae polysaccharide of the ratio of 2:3 by weight.
In one preferred embodiment of the invention, described lentinan or Flos Lonicerae polysaccharide are by such as lower section
Method prepares: after Lentinus Edodes or Flos Lonicerae being pulverized, according to Lentinus Edodes or Flos Lonicerae: water==(0.5g～2.0g): 5
The ratio of mL adds water, and at 70 DEG C～75 DEG C, heated and stirred extracts 3h, filters the filtering residue obtained according to upper
State solid-liquid ratio, temperature and time continues extraction twice, merges three extracting solution, through concentrating under reduced pressure and from
The heart obtains clarification concentrated solution, according to clarification concentrated solution: 95% ethanol=1: the volume ratio of (7～10) is by 7～10
Times volume 95% ethanol joins in clarification concentrated solution, after mixing at 4 DEG C overnight stand precipitation, centrifugal receive
Collection precipitation, i.e. obtains lentinan or Flos Lonicerae polysaccharide through vacuum lyophilization.
According to a third aspect of the present invention, it is provided that a kind of health food prepared according to the method for second aspect
Compositions.
According to a fourth aspect of the present invention, it is provided that a kind of compositions is in preparation prevention and improves chronic enteritis
Purposes in the medicine of disease or health food.
Present aspect one preferred embodiment in, the dosage form of described medicine or health food be capsule,
Tablet, granule, oral liquid, powder, teabag.
By experiment surprisingly, it has been found that the health food of gained of the present invention forms through scientific compatibility, phase
Benefit evident, have no side effect.The most nutritious, there is again prevention and improve chronic enteritis function.
The object of the invention provides a kind of health food and preparation thereof having prevention and improving chronic enteritis effect
Method, confirms simultaneously and evaluates lentinan and whether Flos Lonicerae polysaccharide combination has prevention to chronic enteritis
And improvement result.For achieving the above object, the technical solution adopted in the present invention is to set up TNBS (three nitre
Base benzenesulfonic acid) the rat chronic colitis model induced, determine with this and evaluate polysaccharide and combine chronic enteritis
Prevention and improvement result.Detailed process step is as follows:
First 84 SPF level SD rats are divided into four groups, i.e. blank group, model control group, the positive
Medicine matched group, lentinan group, Flos Lonicerae polysaccharide group, lentinan+Flos Lonicerae polysaccharide group, often organizes 14
Animal, male and female half and half.Weigh before each treated animal preventive administration, then 1 week (perfume of preventive administration
It is each that mushroom polysaccharide group, Flos Lonicerae polysaccharide group, lentinan+Flos Lonicerae polysaccharide group gavage gives corresponding polysaccharide dosage
For 300mg/kg, administration volume is 10mL/kg, and every day 1 time, other three groups give isopyknic animal
Drinking water).After preventive administration terminates, in addition to blank group (giving 50% ethanol), other each group
Use TNBS (trinitro-benzene-sulfonic acid) modeling.Modeling method: animal fasting be can't help after water 24h with 3%
Pentobarbital sodium tail vein injection is anaesthetized, and after Animal Anesthesia, softly inserts colon with disposable blindenea
Injecting modeling medicinal liquid after about 8cm, rat carries tail inversion 60s allows medicinal liquid fully stop colonic.Modeling is tied
After bundle, each treated animal continues to be administered 16 days (lentinan group, Flos Lonicerae polysaccharide group, lentinan+gold silver
Flower polysaccharide group gavage gives corresponding polysaccharide dosage respectively for 300mg/kg, every day 1 time, blank group, mould
Type matched group gives isopyknic animal drinking water, and positive controls gives sulfasalazine enteric coatel tablets suspendible
Liquid, dosage is 600mg/kg).
The feces character (fecal consistency, crissum filth situation) of rat, situation of ingesting is observed during experiment
With mental act state；Measure statistics the weight of animals and body weight increases, Animal diseases activity index after modeling
(DAI), spleen and the organ weights of thymus and organ coefficient, action thing colon pathology inspection of going forward side by side
Look into.By being analyzed comparing to the index of animal pattern, in accordance with the present invention it has now surprisingly been found that, lentinan+gold silver
Flower polysaccharide group compares model control group, and even lentinan group or Flos Lonicerae polysaccharide group, can dramatically increase
The food ration of the chronic enteritis rat model that TNBS (trinitro-benzene-sulfonic acid) induces, and increase its body weight；
The disease activity of the rat chronic colitis model rat that TNBS (trinitro-benzene-sulfonic acid) induces can be significantly reduced
Index (DAI), and reduce its mortality rate, enhancing human body immunity regulating power.
Health food prepared by the present invention is evaluated by preventing and improving chronic enteritis functional experiment and tests
Card, it should be noted that cited embodiment should not be construed as limitation of the present invention.
Chinese medicine composition and preparation method thereof that the present invention provides, purposes and containing this Chinese medicine composition
In medicine, health food, raw materials used and reagent all can be buied by market.
Below in conjunction with embodiment, the present invention it is expanded on further:
The preparation of embodiment 1 lentinan
Lentinan of the present invention is prepared by following preparation method: after being pulverized by Lentinus Edodes, according to
Lentinus Edodes: the ratio of water=0.5g: 5mL adds water, at 70 DEG C, heated and stirred extracts 3h, filters and obtains
Filtering residue continue extraction twice according to above-mentioned solid-liquid ratio, temperature and time, merges three extracting solution, process
Concentrating under reduced pressure and centrifugal acquisition clarify concentrated solution, according to clarification concentrated solution: 95% ethanol=1: the volume ratio of 7
Being joined by 7 times of volume 95% ethanol in clarification concentrated solution, after mixing, at 4 DEG C, overnight stand precipitates, from
The heart collects precipitation, i.e. obtains lentinan through vacuum lyophilization.
The preparation of embodiment 2 Flos Lonicerae polysaccharide
Flos Lonicerae polysaccharide of the present invention is prepared by following preparation method: after being pulverized by Flos Lonicerae,
According to Flos Lonicerae: the ratio of water=2.0g: 5mL adds water, at 75 DEG C, heated and stirred extracts 3h, mistake
The filtering residue that filter obtains continues extraction twice according to above-mentioned solid-liquid ratio, temperature and time, merges three extracting solution,
Concentrated solution is clarified, according to clarification concentrated solution: 95% ethanol=1 through concentrating under reduced pressure and centrifugal acquisition: 10
Volume ratio 10 times of volume 95% ethanol are joined clarification concentrated solution in, after mixing at 4 DEG C overnight stand
Precipitation, centrifugal collecting precipitation, i.e. obtain Flos Lonicerae polysaccharide through vacuum lyophilization.
Embodiment 3 lentinan and the preparation of Flos Lonicerae polysaccharide compositions
Lentinan embodiment 1 prepared and embodiment 2 prepare the ratio of Flos Lonicerae polysaccharide 2:3 by weight
Example mixes, and makes the health-care food composition comprising lentinan and Flos Lonicerae polysaccharide.
Embodiment 4 lentinan and the preparation of Flos Lonicerae polysaccharide compositions
Lentinan embodiment 1 prepared and embodiment 2 prepare the ratio of Flos Lonicerae polysaccharide 1:5 by weight
Example mixes, and makes the health-care food composition comprising lentinan and Flos Lonicerae polysaccharide.
Embodiment 5 lentinan and the preparation of Flos Lonicerae polysaccharide compositions
Lentinan embodiment 1 prepared and embodiment 2 prepare the ratio of Flos Lonicerae polysaccharide 5:1 by weight
Example mixes, and makes the health-care food composition comprising lentinan and Flos Lonicerae polysaccharide.
Embodiment 6 lentinan and the preparation of Flos Lonicerae polysaccharide compositions
Lentinan embodiment 1 prepared and embodiment 2 prepare the ratio of Flos Lonicerae polysaccharide 2:4 by weight
Example mixes, and makes the health-care food composition comprising lentinan and Flos Lonicerae polysaccharide.
Embodiment 7 lentinan and the preparation of Flos Lonicerae polysaccharide compositions
Lentinan embodiment 1 prepared and embodiment 2 prepare the ratio of Flos Lonicerae polysaccharide 4:2 by weight
Example mixes, and makes the health-care food composition comprising lentinan and Flos Lonicerae polysaccharide.
Embodiment 8 lentinan and the Flos Lonicerae polysaccharide combination checking to preventing and improve chronic enteritis function
1, experiment material
1.1, experimental apparatus
Electronic analytical balance (model: FA-B): Hubei Hao Meijia instrument and equipment company limited.
1.2, experiment reagent
TNBS (trinitro-benzene-sulfonic acid), purity > 99% (high-purity level): the permanent remote biotechnology in Shanghai is limited
Company；
Pentobarbital sodium, purity > 99% (high-purity level): Pu Bosi bio tech ltd, Beijing；
Formalin fixative 10%: Yuan Mu bio tech ltd, Shanghai；
Sulfasalazine enteric coatel tablets (specification 0.25g): China Resources Double-Crane Pharmaceutical Co., Ltd..
1.3, laboratory animal and feedstuff
SD rat 84, (no-special pathogen level laboratory animal refers to except clean animal should be arranged SPF level
Except cause of disease in addition to, do not carry important latent infection or opportunistic and to the scientific experiments big cause of disease of interference；
Raise in barrier system, obtained by germfree animal, gnotobiotic animal), 200～300g, 50～
60 days, male female half and half；It is purchased from Hunan Si Laike Jing Da laboratory animal company limited；
Animal maintenance feedstuff title: experimental mouse growth and breeding particulate material (Φ 12mm granule), 25kg/ bag；
It is purchased from Hunan Si Laike Jing Da laboratory animal company limited.
2, EXPERIMENTAL DESIGN
2.1 experiment packet and animal models
Experiment packet: the present embodiment uses SPF level SD rat 84, is divided into blank group, model pair
The Flos Lonicerae prepared according to group, positive drug control group, the lentinan group of embodiment 1 preparation, embodiment 2 is many
Sugar group, the lentinan+Flos Lonicerae polysaccharide group of embodiment 3 preparation, often 14 animals of group, male and female half and half.
Zooprophylazis is weighed before being administered, then preventive administration 1 week；Embodiment 1 preparation lentinan group,
The Flos Lonicerae polysaccharide group of embodiment 2 preparation, the lentinan+Flos Lonicerae polysaccharide group gavage of embodiment 3 preparation are given
Giving corresponding polysaccharide dosage is respectively 300mg/kg, and administration volume is 10mL/kg, every day 1 time, gives for other three groups
Giving isopyknic animal drinking water, the animal of other groups gives equivalent drinking water.After preventive administration terminates,
Blank group gives the 1:1 dehydrated alcohol of dilution, and other are respectively organized and use TNBS (trinitro-benzene-sulfonic acid) to make
Mould.
Modeling method: after preventive administration terminates, 3% pentobarbital sodium is used in animal fasting after can't help water 24h
Tail vein injection is anaesthetized, and after Animal Anesthesia, notes after softly inserting colon about 8cm with disposable blindenea
Entering modeling medicinal liquid, rat carries tail inversion 60s allows medicinal liquid fully stop colonic.Modeling terminates rear each treated animal
Continue be administered 16 days (embodiment 1 preparation lentinan group, embodiment 2 preparation Flos Lonicerae polysaccharide group,
It is respectively 300 that the lentinan+Flos Lonicerae polysaccharide group gavage of embodiment 3 preparation gives corresponding polysaccharide dosage
Mg/kg, every day 1 time, blank group, model control group give isopyknic animal drinking water, positive
Matched group gives sulfasalazine enteric coatel tablets suspension, and dosage is 600mg/kg).
2.2 observation index and detection method
Overview and weighing: observe feces character (fecal consistency, the crissum filth feelings of rat every day
Condition), situation of ingesting and mental act state, weigh weekly twice；According to the index of table 1, calculate modeling
Rear Animal diseases activity index (DAI).
Table 1
Note: DAI=(weight loss mark+feces character mark+fecal occult blood mark)/3
Colon perusal: animal is administered after terminating with 3% pentobarbital sodium tail vein injection anesthesia (30
Mg/kg) put to death after abdominal aortic blood after anesthesia, take lower distal colon about 8cm, cut off intestinal tube along the longitudinal axis,
0.9%NaCl solution carries out colonic pathological change macroscopic score after rinsing well, according to table 2 colon macroscopic score
Standard is marked.
Table 2
Colon pathological examination: take away from the impaired colon of anus about 8cm, the fixing routine of neutral formalin
Paraffin wax flaking, H-E dyes, then carries out histopathological examination.To inflammatory cell (neutrophilic granulocyte and
Lymphocyte) infiltrate and mark by table 3.
Table 3
Additionally, also to mortality rate after the food ration of animal, animal model after preventive administration and modeling,
Thymus and the data such as spleen organ weights and organ coefficient are added up.
The most each index, the continuous data (the weight of animals) in different sexes, group, to each standard
Calculate mean+SD, use SPSS statistical software to process.Adopt according to different data types
By different processing methods, during P 0.05, think that difference has statistical significance.Pathological examination occurs different
Reason condition then needs to compare by between its incidence rate and degree group.Use when homogeneity of variance and normal distribution
One-way ANOVA, between each group, multiple comparisons uses the inspection of Dunnett-t method；Heterogeneity of variance or anon-normal
Using Kruskal-Wallis inspection during state distribution, between each group, multiple comparisons uses the inspection of Dunnett-t method.
2.3, interpretation of result
When zooprophylazis is administered, overview shows no obvious abnormalities.In addition to blank group, other animals
All occur after modeling having loose bowels, crissum filthy serious, the mental status is the best, rough coat, food ration is obvious
Reduce.
Table 4 is the food ration data statistics result of animal after preventive administration and modeling.Therefrom can see
Going out, during zooprophylazis is administered, each treated animal food ration has no significant difference；After modeling three days, with
Model control group compares, embodiment 1 preparation lentinan group, embodiment 2 preparation Flos Lonicerae polysaccharide group,
Animal indivedual period food ration of the lentinan+Flos Lonicerae polysaccharide group of embodiment 3 preparation has no the poorest
Different；But these three groups after modeling the food ration of 6-10 days, 10-13 days and 13-16 days be significantly greater than model comparison
Group, and embodiment 3 preparation lentinan+Flos Lonicerae polysaccharide group animal ingestion amount than other two groups more
Greatly；Compared to blank group, after model control group animal model, food ration reduces.It can thus be appreciated that: real
Lentinan and the Flos Lonicerae polysaccharide combination of executing example 3 preparation can increase TNBS (trinitro-benzene-sulfonic acid) induction
The food ration of chronic enteritis rat model, and than being used alone lentinan or Flos Lonicerae polysaccharide more
Advantage (p < 0.05).
Table 4
Table 5 be animal after preventive administration and modeling weight data statistical result (body weight: x ± SD, single
Position is g).There it can be seen that compared to blank group after modeling, model control group the weight of animals alleviates,
Weightening finish reduces；And other four groups of data show, the lentinan of embodiment 3 preparation and Flos Lonicerae polysaccharide combination
More can increase the body weight of the rat chronic colitis model rat that TNBS (trinitro-benzene-sulfonic acid) induces, and
Ratio is used alone lentinan or Flos Lonicerae polysaccharide more advantage (p < 0.05).
Table 5
(continued 5)
Table 6 is disease activity index (DAI) statistical result after animal model.Compared to blank group,
The disease activity index (DAI) of model comparison treated animal is significantly higher than blank group (p < 0.01)；By
In table, data understand, and lentinan and the Flos Lonicerae polysaccharide combination of embodiment 3 preparation can significantly reduce TNBS
The disease activity index (DAI) of the rat chronic colitis model rat that (trinitro-benzene-sulfonic acid) induces
(p < 0.01), ratio is used alone lentinan or Flos Lonicerae polysaccharide more advantage (p < 0.05).
Table 6
Note: compare with blank group (#P < 0.05, ##p < 0.01)；Compare with model control group (*P < 0.05,
**p<0.01)。
Table 7 is mortality statistics result after animal model.After model control group animal model, mortality rate is significantly high
In blank group (p < 0.05).Understand from data, the lentinan of embodiment 3 preparation and Flos Lonicerae
Polysaccharide combination can reduce the death of the rat chronic colitis model rat that TNBS (trinitro-benzene-sulfonic acid) induces
Rate, and ratio is used alone lentinan or Flos Lonicerae polysaccharide more advantage (p < 0.05).
Table 7
Note: compare (#p < 0.05) with blank group.
Table 8 is the present embodiment animal thymus and spleen organ weights and organ coefficient statistical result.Right with blank
Comparing according to group, model control group animal thymus organ weights and organ coefficient are respectively less than blank group, spleen
Dirty weight and organ coefficient are all higher than blank group.Compared to model control group, embodiment 3 preparation
Lentinan and Flos Lonicerae polysaccharide treated animal thymus organ weights and organ coefficient are all higher than model control group,
Spleen weight and organ coefficient are respectively less than model control group, and lentinan and gold silver prepared by embodiment 3 are described
Flower polysaccharide combination can be obviously enhanced Organism immunoregulation ability, and ratio is used alone lentinan or Flos Lonicerae is many
Sugar has higher (p < 0.05) immunoregulation capability.
Table 8
Note: compare with blank group (#p<0.05)。
The chronic enteritis rat colon pathological changes macroscopic score that table 9 is induced for the present embodiment trinitro-benzene-sulfonic acid
Affect result.Comparing with blank group, model control group animal colon pathological changes macroscopic score improves
(p<0.05).But the lentinan+Flos Lonicerae polysaccharide treated animal colonic pathological change macroscopic score of embodiment 3 preparation
The trend (p < 0.05) of reduction is had compared with other four groups.
Table 9
Note: compare with blank group (#p<0.05)；Each tested material treated animal score value compares with model control group
There was no significant difference (p > 0.05)
Table 10 is that in the present embodiment, the chronic enteritis rat colon damage location of trinitro-benzene-sulfonic acid induction is scorching thin
What born of the same parents infiltrated scoring affects result, its display model control animals and tested material group (positive controls,
The lentinan group of embodiment 1 preparation, the Flos Lonicerae polysaccharide group of embodiment 2 preparation, the perfume (or spice) of embodiment 3 preparation
Mushroom polysaccharide+Flos Lonicerae polysaccharide group) animal colon injury region and colon normally damage the most visible mucosa in junction
Disappearance, neutrophil infiltration, lymphocytic infiltration, downright bad, eosinophils, crypts
Gland is expanded；The a large amount of proliferation of fibrous tissue of Submucosa, edema, neutrophil infiltration, lymphocyte soaks
Profit, eosinophils, hemosiderosis, macrophages infiltration；Muscle layer muscle fiber disappears,
Neutrophil infiltration, lymphocytic infiltration, proliferation of fibrous tissue etc.；Placenta percreta hypertrophy, edema, huge
Phagocyte infiltrations etc. change.But relative model matched group and positive controls, the Lentinus Edodes of embodiment 3 preparation is many
Sugar and Flos Lonicerae polysaccharide combine the rat chronic colitis model rat inducing TNBS (trinitro-benzene-sulfonic acid)
Traumatic Colon low (p < 0.05).
Table 10
Comprehensive data above result is it is found that prepared by the lentinan of embodiment 1 preparation, embodiment 2
Flos Lonicerae polysaccharide can make taking the photograph of chronic enteritis rat model that TNBS (trinitro-benzene-sulfonic acid) induces
Appetite, body weight all increase, and reduce the mortality rate after animal model, enhancing human body immunity regulating power, subtract
Disease activity index (DAI) after light animal model, alleviates colitis symptoms, the most wonderful
Existing, the lentinan of embodiment 3 preparation and the effect of Flos Lonicerae polysaccharide compositions are more excellent.Therefore embodiment 3
The lentinan of preparation and Flos Lonicerae polysaccharide compositions have prevention and improve chronic enteritis effect, and compare
It is used alone lentinan or Flos Lonicerae polysaccharide more advantage (p < 0.05).
Lentinan and Flos Lonicerae polysaccharide compositions according to embodiment 3 preparation have prevention and improve chronic
Enteritis effect, by natural, artificial and above-described embodiment 1 and the preparation method system of embodiment 2
Become lentinan and Flos Lonicerae polysaccharide, by 2:3 proportions (i.e. embodiment 3 preparation compositions,
Test finds that the proportional arrangement effect of 2:3 is the most unexpected), add edible or pharmaceutic adjuvant, can prepare
Become the dosage form of the various health foods such as capsule, tablet, granule, oral liquid, powder, teabag.
The compositions of Example 4～embodiment 7 preparation carries out above-mentioned experiment, experimental result and embodiment 3
The result of compositions of preparation is same or like, and ratio is used alone lentinan or Flos Lonicerae polysaccharide is the most excellent
Gesture (p < 0.05).
The lentinan of embodiment 9 different proportion, Cordyceps polysaccharide compositions and effect thereof
The lentinan, the embodiment 2 that embodiment 1 are prepared prepare Cordyceps polysaccharide with Different Weight in table 11
Meter ratio mixes, and adds medical science or food acceptable carrier, excipient, excipient further and/or fills out
Fill agent.Make the health-care food composition comprising lentinan, Cordyceps polysaccharide.And it is right according to implementing in 4
Prevention and improve chronic enteritis and the verification method of gastrointestinal upset function that causes is prevented and improves slowly
Property enteritis and the gastrointestinal upset function result score value caused thereof.(100 points of systems, with 2:3 in embodiment 3
Mixing quality prevents and improves chronic enteritis and the gastrointestinal upset merit caused thereof accordingly than the compositions prepared
Can be designated as 100 points, other mixed proportions corresponding function test result compares the function examination accounting for embodiment 4
Test the percentage point of result, be designated as corresponding function score value)
The lentinan of table 11 different proportion, Cordyceps polysaccharide compositions and effect thereof
| 1:5 | 5:1 | 1:4.5 | 4.5:1 | 2:4 | 4:2 | |
| Prevent and improve chronic enteritis and the gastrointestinal upset function caused thereof | 78 | 71 | 80 | 73 | 91 | 89 |
Function test is found that lentinan, Cordyceps polysaccharide are when the mixed proportion of (1:5)～(5:1)
Compare and individually use two kinds of polysaccharide there is the intestines and stomach more significantly preventing and improving chronic enteritis and cause
Uncomfortable function.When using polysaccharide mixed proportion for (2:4)～(4:2), effect is more notable.
Health food of the present invention forms through scientific compatibility, brings out the best in each other, and has no side effect；Existing
Nutritive value, has again prevention and improves chronic enteritis function.Applicant states, above content is to combine tool
The embodiment further description made for the present invention of body, it is impossible to assert being embodied as of the present invention
It is confined to these explanations.For general technical staff of the technical field of the invention, do not taking off
On the premise of present inventive concept, it is also possible to make some simple deduction or replace, all should be considered as belonging to
Protection scope of the present invention.
Claims (10)
1. a Chinese medicine composition, it is characterised in that be made up of Lentinus Edodes and Flos Lonicerae.
Chinese medicine composition the most according to claim 1, it is characterised in that effective one-tenth of described Lentinus Edodes
Being divided into lentinan, the effective ingredient of described Flos Lonicerae is Flos Lonicerae polysaccharide.
Chinese medicine composition the most according to claim 2, it is characterised in that described lentinan and institute
The mass ratio stating Flos Lonicerae polysaccharide is (1:5)～(5:1).
Chinese medicine composition the most according to claim 2, it is characterised in that described lentinan and institute
The mass ratio stating Flos Lonicerae polysaccharide is (2:4)～(4:2).
Chinese medicine composition the most according to claim 2, it is characterised in that described lentinan and institute
The mass ratio stating Flos Lonicerae polysaccharide is 2:3.
6., according to the preparation method of the Chinese medicine composition described in any one of claim 1 to 5, its feature exists
In, take described Lentinus Edodes or described Flos Lonicerae is pulverized, in terms of g/mL, respectively according to Lentinus Edodes or Flos Lonicerae and water
The ratio that mass volume ratio is (0.5g～2.0g): 5mL mixing, carry at 70 DEG C～75 DEG C of heated and stirred
Take 3h, filter the filtering residue obtained and continue extraction twice according to above-mentioned solid-liquid ratio, temperature and time, merge three
Secondary extracting solution, clarifies concentrated solution, according to described clarification concentrated solution and 95% through concentrating under reduced pressure and centrifugal acquisition
The volume ratio of ethanol is 1: (7～10) mix, and precipitates in 4 DEG C of overnight stand after mixing, and centrifugal collection is sunk
Form sediment, through vacuum lyophilization and get final product.
The Chinese medicine composition that preparation method the most according to claim 6 prepares.
8. according to the Chinese medicine composition described in any one of claim 1 to 5 and/or according to claim 7 institute
The Chinese medicine composition stated preparation prevention and/or improve chronic enteritis and the medicine of gastrointestinal upset caused thereof and
/ or health food in purposes.
Purposes the most according to claim 8, it is characterised in that in described Chinese medicine composition, described
Lentinan is respectively 300mg/kg with the using dosage of described Flos Lonicerae polysaccharide.
10. one kind for preventing and/or improve chronic enteritis and the medicine of gastrointestinal upset caused thereof and/or guarantor
Health food, it is characterised in that include the Chinese medicine composition as described in any one of claim 1 to 5 and/or
Chinese medicine composition as claimed in claim 7 and pharmaceutically acceptable adjuvant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610379155.XA CN105878331A (en) | 2016-05-31 | 2016-05-31 | Polysaccharide composition and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610379155.XA CN105878331A (en) | 2016-05-31 | 2016-05-31 | Polysaccharide composition and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105878331A true CN105878331A (en) | 2016-08-24 |
Family
ID=56710865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610379155.XA Withdrawn CN105878331A (en) | 2016-05-31 | 2016-05-31 | Polysaccharide composition and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105878331A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108142923A (en) * | 2018-03-14 | 2018-06-12 | 广东省微生物研究所（广东省微生物分析检测中心） | Purposes of the mushroom dietary fiber extract in the preparation for preparing treatment and/or prevention intestinal bacilli illness relevant disease |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102512438A (en) * | 2011-12-16 | 2012-06-27 | 福建省闽东力捷迅药业有限公司 | Application of pseudostellaria polysaccharide in food for preventing and treating diabetes mellitus as well as health-caring |
| CN102702582A (en) * | 2011-11-07 | 2012-10-03 | 赛珂睿德生物医药科技(上海)有限公司 | Zeamays L. polysaccharide and preparation method and application thereof |
| CN104546889A (en) * | 2014-12-04 | 2015-04-29 | 无限极（中国）有限公司 | Application of lentinan in preparing medicine, healthcare product and food in treating or preventing disease caused by enteric flora disturbance |
-
2016
- 2016-05-31 CN CN201610379155.XA patent/CN105878331A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102702582A (en) * | 2011-11-07 | 2012-10-03 | 赛珂睿德生物医药科技(上海)有限公司 | Zeamays L. polysaccharide and preparation method and application thereof |
| CN102512438A (en) * | 2011-12-16 | 2012-06-27 | 福建省闽东力捷迅药业有限公司 | Application of pseudostellaria polysaccharide in food for preventing and treating diabetes mellitus as well as health-caring |
| CN104546889A (en) * | 2014-12-04 | 2015-04-29 | 无限极（中国）有限公司 | Application of lentinan in preparing medicine, healthcare product and food in treating or preventing disease caused by enteric flora disturbance |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108142923A (en) * | 2018-03-14 | 2018-06-12 | 广东省微生物研究所（广东省微生物分析检测中心） | Purposes of the mushroom dietary fiber extract in the preparation for preparing treatment and/or prevention intestinal bacilli illness relevant disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103830577B (en) | A kind of medical composition and its use treating hepatobiliary calculus and urinary stone disease | |
| CN102240318B (en) | Preparation method and analysis method of traditional Chinese medicine for tonifying qi and increasing breast milk | |
| CN102551046B (en) | Natural health composition for weight reduction and application of same | |
| TW200425905A (en) | Therapeutical composition for hepatitis C | |
| CN105055855B (en) | With Chinese medicine composition for improving sleep, strengthen immunity effect and its preparation method and application | |
| CN101002929A (en) | Medicine for treating functional hypopepsia or complicating Helicobacter pylori infection, and its preparing method | |
| CN105902597A (en) | Polysaccharide composition, preparation method and use thereof | |
| CN106177432A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja, Folium Mori, green tea and Rhizoma Polygonati Odorati | |
| CN106729568A (en) | A kind of drug regimen for treating ulcerative colitis | |
| CN105770409B (en) | Have effects that promote the Chinese medicine composition and its preparation method and application of lactation | |
| CN103920140B (en) | A kind of people is with blood sugar lowering Weight-reducing and lipid-lowering compound preparation | |
| CN113952419B (en) | Pharmaceutical composition for chronic renal failure and preparation method and application thereof | |
| CN105878331A (en) | Polysaccharide composition and preparation method and application thereof | |
| CN101850063A (en) | Medicinal preparation for preventing and treating gout and preparation method | |
| CN102266428B (en) | Anti-ageing Chinese medicinal composition and preparation method and application thereof | |
| CN104548016A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating hyperuricemia | |
| CN105056128A (en) | Traditional Chinese medicine composition for treating chronic atrophic gastritis and intestinal metaplasia and preparation method and application thereof | |
| CN104888157A (en) | Traditional Chinese medicine preparation for treating hysteromyoma and preparation method thereof | |
| CN104721256A (en) | Anwei Yang extract as well as preparation method and medical application thereof | |
| CN104043042A (en) | Traditional Chinese medicine composition for treating hepatic calculus | |
| CN106038977A (en) | Polysaccharide composite, preparing method and application of polysaccharide composite | |
| CN103933154B (en) | A kind of Chinese medicine composition treating goat and preparation method thereof | |
| CN104352797A (en) | Traditional Chinese medicine for treating advanced lung cancer and application of traditional Chinese medicine | |
| CN104758705A (en) | Traditional Chinese medicine composition for treating chronic glomerulo nephritis and preparation method thereof | |
| CN110064016A (en) | A kind of Chinese medicine composition and preparation method thereof adjusting chronic kidney disease immune state |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160824 |
|
| WW01 | Invention patent application withdrawn after publication |